A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors

Clinical trial NCT06524804 · TERMINATED

Trial details

NCT number: NCT06524804
Sponsor: Chengdu Baiyu Pharmaceutical Co., Ltd.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2024-05-15
Primary completion: 2024-10-18
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.